2023
DOI: 10.22146/jtbb.80975
|View full text |Cite
|
Sign up to set email alerts
|

The Synergistic Effect of Combination of Pentagamavunone-1 with Diosmin, Galangin, and Piperine in WiDr Colon Cancer Cells: <i>In vitro</i> and Target Protein Prediction

Muthi Ikawati,
Hajidah Musyayyadah,
Yurananda Magnalia Putri
et al.

Abstract: Pentagamavunone-1 (PGV-1) is a curcumin analog with a prominent anti-cancer potency in vitro and in vivo for several cancer types, including colon cancer. Combining PGV-1 with natural compounds such as diosmin, galangin, and piperine can enhance its effectiveness due to their promising chemoprevention properties. We aimed to evaluate the effectiveness of combining PGV-1 with diosmin, galangin, or piperine for colon cancer by using in vitro and bioinformatic approaches to predict their target proteins. WiDr cel… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 31 publications
0
1
0
Order By: Relevance
“…For example, diosmin with PGV-1 synergistically enhances their cytotoxicity through modulation of senescence and mitotic catastrophe in TNBC 4T1 cells (Musyayyadah et al 2021). Diosmin also enhances the cytotoxicity of PGV-1 in colon cancer cells (Ikawati et al 2023). In accordance to those findings, the combination of a chemotherapy agent doxorubicin with hesperidin and its aglycone form, hesperitin, synergistically inhibits the migration of 4T1 and MCF7/HER2 cells (Nurhayati et al 2020;Amalina et al 2023).…”
Section: Introductionmentioning
confidence: 86%
“…For example, diosmin with PGV-1 synergistically enhances their cytotoxicity through modulation of senescence and mitotic catastrophe in TNBC 4T1 cells (Musyayyadah et al 2021). Diosmin also enhances the cytotoxicity of PGV-1 in colon cancer cells (Ikawati et al 2023). In accordance to those findings, the combination of a chemotherapy agent doxorubicin with hesperidin and its aglycone form, hesperitin, synergistically inhibits the migration of 4T1 and MCF7/HER2 cells (Nurhayati et al 2020;Amalina et al 2023).…”
Section: Introductionmentioning
confidence: 86%